Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway-Reference-Cited by-同舟云学术

Sacubitril/valsartan (LCZ696) reduces myocardial injury following myocardial infarction by inhibiting NLRP3‑induced pyroptosis via the TAK1/JNK signaling pathway

Published:2021-07-23 Issue:3 Volume:24 Page:
ISSN:1791-2997
Container-title:Molecular Medicine Reports
language:
Short-container-title:Mol Med Rep

Author:

Shen Jianfen¹,Fan Zhongbao²,Sun Guang³,Qi Guoxian³

Affiliation:

1. Department of Cardiology, The First Affiliated Hospital of China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China

2. Department of Hepatobiliary Surgery, People's Hospital of China Medical University, Liaoning Provincial People's Hospital, Shenyang, Liaoning 110016, P.R. China

3. Department of Geriatric Cardiology, The First Affiliated Hospital of China Medical University, Heping, Shenyang, Liaoning 110001, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,Genetics,Molecular Biology,Molecular Medicine,Biochemistry

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Epigenetic regulation of diverse regulated cell death modalities in cardiovascular disease: Insights into necroptosis, pyroptosis, ferroptosis, and cuproptosis;Redox Biology;2024-10

2. Sacubitril/valsartan alleviates myocardial infarction-induced inflammation in mice by promoting M2 macrophage polarisation via regulation of PI3K/Akt pathway;Acta Cardiologica;2024-09-11

3. Sacubitril/valsartan alleviates sepsis-induced myocardial injury in rats via dual angiotensin receptor-neprilysin inhibition and modulation of inflammasome/caspase 1/IL1β pathway;European Journal of Pharmacology;2024-09

4. Programmed death of cardiomyocytes in cardiovascular disease and new therapeutic approaches;Pharmacological Research;2024-08

5. Targeting MAPK-ERK/JNK pathway: A potential intervention mechanism of myocardial fibrosis in heart failure;Biomedicine & Pharmacotherapy;2024-04